Company news
Revolution Medicines, Inc. (NASDAQ:RVMD) news
Every Revolution Medicines, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 3
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
August 17, 2023
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
August 8, 2023
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
August 3, 2023
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
August 1, 2023
Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
May 24, 2023
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
May 8, 2023
Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023
May 1, 2023
Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference
April 13, 2023
Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
April 6, 2023
Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
March 7, 2023
Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock
March 2, 2023
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
February 27, 2023
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
February 21, 2023
Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023
Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor
December 19, 2022
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
December 7, 2022
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
November 7, 2022
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
November 1, 2022
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
September 22, 2022
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
September 1, 2022
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
August 9, 2022
Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022
July 28, 2022
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
July 22, 2022
Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
July 19, 2022
Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors
July 13, 2022
Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236
June 28, 2022
Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
June 9, 2022
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress
May 9, 2022
Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022
April 21, 2022
Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
March 9, 2022
Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference
March 1, 2022
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress
February 28, 2022
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022
February 22, 2022
Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
February 3, 2022
Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference
January 11, 2022
Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference
November 24, 2021
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
November 10, 2021
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
November 8, 2021
Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
November 3, 2021
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
September 15, 2021
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 7, 2021
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
August 11, 2021
Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
August 4, 2021
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
June 24, 2021
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
June 10, 2021
Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
June 2, 2021
Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
May 18, 2021
Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress
May 10, 2021